Insight Molecular Diagnostics (IMDX) Non Operating Investment Income (2020 - 2023)
Historic Non Operating Investment Income for Insight Molecular Diagnostics (IMDX) over the last 4 years, with Q4 2023 value amounting to -$69000.0.
- Insight Molecular Diagnostics' Non Operating Investment Income fell 59285.71% to -$69000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was -$61000.0, marking a year-over-year increase of 8704.88%. This contributed to the annual value of -$61000.0 for FY2023, which is 8704.88% up from last year.
- Latest data reveals that Insight Molecular Diagnostics reported Non Operating Investment Income of -$69000.0 as of Q4 2023, which was down 59285.71% from -$89000.0 recorded in Q3 2023.
- In the past 5 years, Insight Molecular Diagnostics' Non Operating Investment Income registered a high of $315000.0 during Q4 2020, and its lowest value of -$330000.0 during Q1 2022.
- Its 4-year average for Non Operating Investment Income is -$312.5, with a median of -$7000.0 in 2021.
- Over the last 5 years, Insight Molecular Diagnostics' Non Operating Investment Income had its largest YoY gain of 98125.0% in 2021, and its largest YoY loss of 79000.0% in 2021.
- Quarter analysis of 4 years shows Insight Molecular Diagnostics' Non Operating Investment Income stood at $315000.0 in 2020, then tumbled by 106.03% to -$19000.0 in 2021, then skyrocketed by 173.68% to $14000.0 in 2022, then tumbled by 592.86% to -$69000.0 in 2023.
- Its Non Operating Investment Income was -$69000.0 in Q4 2023, compared to -$89000.0 in Q3 2023 and -$24000.0 in Q2 2023.